Efemoral Medical announced the presentation of long-term results from the initial 20 patients enrolled across four sites in ...

Surmodics, Inc. announced the publication of results from the TRANSCEND clinical trial. The global randomized study ...

The initial long-term results from EFEMORAL I were presented today by Principal Investigator Prof. Andrew Holden (Auckland ...

A total of 446 patients with femoropopliteal artery disease (Rutherford stages 2–4) were randomized to either the SurVeil DCB (n = 222) or the IN.PACT Admiral DCB (n = 224). Patients were ...

"Compared to balloon angioplasty or self-expanding nitinol stents that are commonly used to treat patients with narrowing in their femoropopliteal artery, balloon expandable scaffolds with high ...

The type of surgery used to treat PAD will depend on the size and location of the affected leg artery or arteries. Surgeries include: Aortobifemoral bypass.Femoropopliteal (fem-pop) ...

The prospective, multi-center, single-blind, randomized, controlled TRANSCEND study compared the SurVeil DCB and the IN.PACT Admiral DCB for treating superficial femoral and proximal popliteal artery ...

Surmodics (SRDX) announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil drug-coated ...